Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion Nutraveda's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 75.1.
Accretion Nutraveda's Days Inventory for the
six
months ended in Mar. 2026 was 88.69.
Accretion Nutraveda's Days Payable for the
six
months ended in Mar. 2026 was 23.39.
Therefore, Accretion Nutraveda's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 140.40.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Accretion Nutraveda Cash Conversion Cycle Related Terms
Accretion Nutraveda Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda Cash Conversion Cycle Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Cash Conversion Cycle
32.28
101.84
129.70
151.10
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Cash Conversion Cycle
0.00
0.00
93.58
127.65
140.40
BOM:544694 vs ZTS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Accretion Nutraveda's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a Cash Conversion Cycle of 140.40 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Accretion Nutraveda and its competitors.
Is Accretion Nutraveda's Cash Conversion Cycle too high?
Accretion Nutraveda's current Cash Conversion Cycle is 140.40. The Drug Manufacturers industry median Cash Conversion Cycle is 145.72. Accretion Nutraveda's value of 140.40 is 3.6% below this industry median. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Cash Conversion Cycle compare to ZTS?
Accretion Nutraveda's Cash Conversion Cycle of 140.40 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.72. Accretion Nutraveda's value of 140.40 is 3.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.72, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current Cash Conversion Cycle of 140.40 is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Cash Conversion Cycle is 140.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Cash Conversion Cycle of 140.40. The current Cash Conversion Cycle is 140.40 and 3.6% below the Drug Manufacturers industry median of 145.72. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Cash Conversion Cycle is 140.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
